Why hypes & hers health, Inc. (Hymps) increased last week

We recently published a list of These 10 companies increased last week, here is why. In this article, let’s take a look at where Hirs & Hers Health, Inc. (NYSE: HIMS) is against other companies that increased last week.

Last negotiation week, a quieter, generally optimistic environment was in the midst of the temporary pause of Tit-Pertat rates, which increased even more by a large number of corporate gains during the first quarter of the year.

The week a week, the Nasdaq Tech-Heavy accumulated the maximum, 3.4 percent, followed by the Dow Jones with 3 percent and the S&P 500 percent.

Beyond the main rates, 10 companies were highlighted, reserving two -digit gains to 48 percent, thanks to the profits and the best prospects than expected.

In this article, we name the ten best performance companies this week and detail the reasons for their benefits.

To present the list, we only considered shares with market capitalization of $ 2 billion and a negotiation volume of $ 5 million. Stocks were chosen based on the highest percentage of the closing prices on May 2 in front of their prices one week before or on April 25.

A nurse on a telehealth platform talking to a consultation patient for consultation.

Hys & Hers Health, Inc. (NYSE: Hymps)

HIMS & Hers jumped 45.3 percent of a week to end $ 40.82 on Friday, compared to $ 28.09 the previous week, as a news story, which achieved a long -term collaboration with the new appetite for the new and the new participation of investors.

According to the company, it will announce the results of its results after the market closes on Monday, May 5, 2025, where investors will close their updated perspective orientation for the rest of the year.

In the recent news, Hirs & Hers Health, Inc. (NYSE: HIMS) reached a long -term agreement with Novo Nordisk to jointly market the Blockbuster weight loss drug, Wegovy.

With the collaboration, the company said that the North -Americans can now access the Novocare Pharmacy directly through its platform, with a grouped offer of all Wegovy’s dose forces and a member HIMS & Hers, including access to care 24 hours a day, continuous clinical support and nutritional orientation, among others.

It can be known that the His used to make a composite version of the treatment that helped boost their sales in recent years. It was later suspended after the Food and Drug administration announced that Novo Nordisk had already produced a sufficient supply of treatment.

Generally, Hymps Ranks 2nd In our list of companies that increased last week. Although we recognize the potential of His as an investment, our conviction lies in the belief that the AI ​​actions have a greater promise to obtain higher yields and to do it in a shorter period. There is an AI stock that increased since the beginning of 2025, while the popular AI actions lost around 25%. If you are looking for a stock of Ia most promising than His but sells less than five times, see our report on this the cheapest you have stockk.